Terence W. Friedlander

MD

Genitourinary oncologist
Medical oncologist who loves to travel and play tennis

Dr. Terence Friedlander specializes in cancers of the genital and urinary organs, in particular bladder and prostate cancers. His research focuses on understanding the basic biology of these diseases and developing new ways to overcome resistance to treatments.

Friedlander earned his medical degree at New York University School of Medicine and completed a residency in internal medicine at UCSF. He received a Fulbright scholarship in 2006 to study medical ethics, and he completed a fellowship in hematology and oncology at UCSF, when he served as chief fellow. He has also received an American Society of Clinical Oncology Young Investigator Award.

Friedlander is a member of the American Society of Clinical Oncology and American Association for Cancer Research.

  • Education

    New York University School of Medicine, 2003

  • Residencies

    UCSF Medical Center, Internal Medicine, 2006

  • Fellowships

    UCSF Medical Center, Hematology-Oncology, 2010

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

  • Languages

    Spanish

With so many new options available for urologic cancers, my hope is that we can harness these treatments to help all our patients.

Conditions I specialize in

Where I see patients (2)

    My reviews

    5.0

    Overall Experience
    140 Ratings
    Explained things in a way that was easy to understand
    139 Ratings
    Did the doctor pay attention to your concerns
    140 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    139 Ratings
    Knew the important information about your medical history
    139 Ratings
    The provider showed respect for what you had to say
    140 Ratings
    The provider spent enough time with me
    140 Ratings
    Read all reviews About our process

    Selected research

    Decorative Caduceus

    Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combina...

    Objective response rate, defined as the proportion of participants with a CR or PR on two consecutive occasions >=4 weeks apart during Stage 1, as determined by the investigator according to RECIST v1.1.

    Recruiting

    Decorative Caduceus

    A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

    Descriptive statistics will be used to summarize results.

    Recruiting

    Contact me

    Providers on my team

    Share